Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies

Atherosclerosis

Volumn 93, Issue 1-2, 1992, Pages 105-113

  Hoffman, Ron ^a   Brook, Gerald J ^a   Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anti oxidants; Atherosclerosis; Bezafibrate; Cholestyramine; Hypercholesterolemia; Lipoprotein oxidation; Pravastatin

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; COLESTYRAMINE; PRAVASTATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID PEROXIDATION; MACROPHAGE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANIMAL; ANTILIPEMIC AGENTS; BEZAFIBRATE; CELLS, CULTURED; CHOLESTEROL; CHOLESTYRAMINE; ESTERIFICATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LIPOPROTEINS, LDL CHOLESTEROL; MACROPHAGES; MALE; MALONDIALDEHYDE; MICE; MIDDLE AGE; PRAVASTATIN; VITAMIN E;

EID: 0026689102     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(92)90204-T     Document Type: Article

References (42)

1. Modification of low density lipoprotein that increase its atherogenicity
2. The role of monocytes in atherosclerosis
3. Effect of lipoproteins and platelets on macrophage cholesterol metabolism
4. Lipoprotein metabolism in the macrophage: implication for cholesterol deposition in atherosclerosis
5. The role of altered lipoproteins in the pathogenesis of atherosclerosis
6. Free radical modification of low density lipoproteins machanism and biological consequences
7. Malondialdehyde affects the physicochemical and biological characteristics of oxidized low density lipoprotein
8. Vitamin E and other lipophylic antioxidants protect LDL against oxidation
9. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients
10. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophages rich fatty streaks and slow the progression of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbit
11. Probucol inhibits oxidative modification of low density lipoprotein
12. Studies on the mechanism of action of probucol
13. Mevinolin: a highly potent competitive inhibitor of hydroxy methyl glutaryl CoA reductase and cholesterol
14. Lovastatin inhibits LDL oxidation
15. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia
16. Influence of pravastatin a specific inhibitor of HMG CoA reductase on hepatic metabolism of cholesterol
17. Bile sequestrant therapy alters the composition of low density and high density lipoproteins
18. Fibric acid effects on lipids and lipoprotein metabolism
19. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperproteinemic patients
20. Immunologic assays of apolipoproteins A, AI, All and B in serum
21. Microsomal lipid peroxidation
22. Spectrophotometeric assay for lipid peroxides in serum lipoproteins using a commercially available reagent
23. Rapid determination of tocopherol in macro and micro quantities of plasma, Results obtained in various nutrition and metabolic studies
24. Electrophoresis and sudan black staining of lipoproteins on gelatinised cellulose acetate
25. Platelet secretory products increase LDL oxidation, enhance its uptake by macrophages and reduce its fluidity
26. Lipoprotein uptake and metabolism by rat aortic smooth muscle cells in tissue culture
27. Protein measurement with the Folin reagent
28. Influence of lovastatin on concentrations and composition of lipoprotein subfractions
29. Effects of lovastatin therapy on guinea pig low density lipoprotein composition and metabolism
30. Low density lipoprotein density and composition in hypercholesterolemic men treated with HMG CoA reductase inhibitors and gemfibrozil
31. Cholestyramine induced changes in low density lipoprotein composition and metabolism. I. studies in the guinea pig
32. Bile sequestrant therapy alters the composition of low density lipoprotein and high density lipoprotein
33. Fenofibrate affects the composition of lipoproteins
34. Change in very low, low and high density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type Ila and type IIb hyperlipoproteinemia
35. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects
36. Distribution of tocopherol in human plasma lipoproteins
37. Antioxidant therapy and uptake of human oxidized LDL by macrophage
38. Modification of low density lipoproteins from hypertriglyceridemic patients by macrophages in vitro and the effect of bezafibrate treatment
39. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations
40. Dual effect of lovastatin and simvastatin on LDL-macrophage interaction
41. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens
42. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor